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Background: Shark liver oil (SLO) contains both alkylglycerols (AKG) and squalene and is an ancient remedy among
the fishermen on the west coast of Norway and Sweden. Literature reports showed that alkyglycerols enhance
Fc–receptor mediated phagocytosis, increase humoral immune response and delay hypersensitivity reactions.
Methods: On this background we performed an open spontaneous study on 40 very old aged surgical patients
preoperatively treated with alkyglycerols (500 mg twice a day for 4 weeks), in order to reduce the risks of operation,
counteracting the postoperative inflammatory and anergic conditions thus achieving quick and plain recovery. To
better understand the possible therapeutic impact of alkyglycerols we compared on a case/control basis treated
versus untreated patients submitted contemporarily to the identical operation and exposed to the same
environmental and seasonal risks.
Results: The onset of complications was reduced in the alkyglycerols treated group and the compliance to the
natural treatment was excellent without any serious adverse effect. WBC count and IgG significant increase
(respectively p <0.05 and p <0.001) might explain some sort of protection against infectious agents and wound
repair adverse events. Also lymphocytes concentration significantly increased in the AKG treated group (p <0.001)
whereas a slight decrease was observed in the control group. Conversely neutrophils significantly decreased in the
AKG treated group (p <0.001) meaning that patients have no more infections and have re-established their
physiologic state. However a significant increase was observed in the control group (p <0.05). CRP significantly
decreased in the group receiving AKG (p <0.05), thus evidencing a slight antiinflammtory effect of the product.
Also ESR decreased from a baseline in the group receiving AKG.
Conclusions: In conclusion we suggest the opportunity to introduce this nutraceutical product in dosages of 500
mg twice a day to very old people before surgical treatment for an effective modulation of leukocytes and soluble
immune reactivity according with the shark liver oil consumption trend in the northern Europe countries folk
medicine. For this reason it might be advisable a wider study on a substantially bigger patients cohort focused on
the complication rate prevention or control.
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Shark liver oil (SLO) contains both alkylglycerols (AKG)
and squalene and is an ancient remedy among the fisher-
men along the west coast of Norway and Sweden. It has
been successfully used for wound healing [1], inflammatory
lung [1] and alimentary tract [2] diseases, lymphadenop-
athy [3], cancer [4] and dermatitis [5]. In 1922 Tsujimoto* Correspondence: alessandro811@hotmail.it
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unless otherwise stated.and Toyama found AKG in SLO [6] and Sir Robert
Robinson, a Nobel laureate, first synthesized them in 1930
[7]. In the natural sources, they are always found esterified
with fatty acids. Structurally they are alkyl ethers of glycerol
(Figure 1).
Brohult and Holmberg [8], using the unsaponifiable por-
tion of different bone marrow fats as well as preparations
containing esters of AKG in child leukemia, observed a
pro-differentiating effect on the white blood cells leading
to AKG clinical administration in actinic leucopenia [9].
In the early 1950s Astrid Brohult began experimentingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 AKG chemical structure.
Table 1 AKG percentage in human bone marrow, human









16:0 29.4 23.9 9.1
16:1 Trace 10.8
17 a 7.6 3.6 3.6
18:0 24.6 22.8 2.8
18:1 16.7 33.8 59.4
18:2 1.4 1.6
18:3
19a 6.1 2.4 1.5
20:0 2.9 1.6
20:1 3.2 2.3 6.2
22:0 0.7 0.7
22:1 5.1 3.4 2.2
24 2.1
The number of carbon atoms in the first column refers to the long-chain
component of the molecule. The number after the column denotes the
number of double bonds. aBoth branched and normal chains C15, C17, and C19
are present [1].
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mia, highlighting their property to stimulate white blood
cells production and later, in 1963, she published a thesis
on AKG and their use in uterine cancer irradiated patients
demonstrating that AKG administration during radio-
activity exposure reduced the bone marrow induced
leukopenia following radiation therapy for uterine cervix
carcinoma [10]. AKG treated patients showed a reduced
complication rate and 47% fistula incidence reduction
when AKG had been administered prior to radiation treat-
ment [11,12].
The principal AKG include chimyl (hexadecyl), batyl
(octadecyl) and selachyl (octadecyl) ethers. Hallgreen
et al. reported that glycerol ethers occur in the tissues in
the form of diesters and alkyl acyl phosphatides [13]. 1-
O-Alkylglycerols and 1-O-(2-methoxyalkyl) glycerols
were isolated from the neutral lipids and phospholipids
of human colostrum, human milk, cow’s milk, sheep’s
milk, human red bone marrow, red cells, blood plasma,
and a uterine carcinoma (Table 1).
AKG and alkyl lysophospholipids significantly activate
cytotoxic macrophages leading to enhanced Fc–receptor
mediated phagocytosis and increase humoral immune re-
sponse and delayed hypersensitivity reaction [14]. AKG
have been shown to stimulate hematopoiesis, erythropoi-
esis, thrombocytosis and granulocytosis in experimental
animals [15]. The anticancer effect of AKG might be
due, according to the previously described studies, to
the property of activating macrophages, and increasing
the cytokines production such as Interleukine-12 (IL-
12) and Interferon-gamma (IFN-γ). Recruitment and ac-
tivation of macrophages, in fact, is acknowledged to be
fundamental in the primary antitumor defence [16];
while IFN-γ, (a T-cell derived lymphokine), inhibits awide number of malignant cells either directly counter-
acting cancer cells growth or through its immunomodu-
latory properties [17], IL-12 induces IFN-γ secretion
from naive and activated T and natural killer (NK) cells,
enhances the cytotoxic activity of NK cells, cytotoxic T
lymphocytes and lymphokine activated killer cells, in-
creases of the proliferation of pre-activated T cells
and NK cells, with a key role in the tumors defence
[18-20]. On this basis, considering the potential bene-
fits that AKG administration might have on very old
pericentenarian patients submitted to surgery (we
enclosed this ultra aged cohort of surgical candidates
in the naïve term of “Jurassic surgery”), we adminis-
tered such compounds to 40 very old patients before
surgical intervention in order to reduce the risks of
operation and to achieve the best compliance and
quick recovery.
We run an open spontaneous study on 40 operated
cases comparing treated versus untreated patients under-
gone the same type of operation during the same histor-
ical period and the same environmental and seasonal
risks.
Results and discussion
Results clearly indicate a significant increase of WBC
concentration was observed in the AKG treated group,
from a baseline value of 5071 ± 236.4 per μl to 8309 ±
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hanced physiological response to the surgical trauma
and wound remodeling (Figure 2A).
Post operative immunoglobulins dosage of AKG treated
patients revealed significant increase of both IgM
(Figure 2E), from a baseline value of 54.95 ± 2.26 mg/dl to
99.47 ± 5.31 mg/100 ml (p <0.001), and IgA (Figure 2F),
from a baseline value of 66.4 ± 3.62 to 103.6 ± 6.18 mg/100
ml (p <0.001), as a definite reaction against sorting infec-
tious agents either in the sutured wound area or in the re-
spiratory and urinary tract (IgA). As to IgG an overall
increase was observed both in AKG treated group, from
a baseline value of 718.9 ± 27.34 to 1008.6 ± 52.69 mg/
100 ml, meaning that the activation of plasma cells
already primed for specific antibody response especiallyFigure 2 Measurements of biochemical parameters. A. Schematic repre
meaning a enhanced physiological response to the surgical trauma and wo
neutrophils in the AKG treated group meaning the absence of infections a
the increase of lymphocytes in the AKG treated group; D-F. Schematic repr
the AKG treated group, meaning an activation of plasma cells primed for s
infectious agents, respectively; G. Schematic representation of the decrease
effect of the product; H. Schematic representation of the decrease of ESR iagainst infectious bacteria and fungi was occurred, and in
the control group, from a baseline value of 822.2 ± 63.98
to 930.6 ± 49.17 mg/100 ml. Also lymphocytes concentra-
tion significantly increased in the AKG treated group from
a baseline value of 26.0 ± 3.31 × 109 L to 30.50 ± 1.13 ×
109 L (p <0.001); whereas a slight decrease, from a base-
line value of 26.60 ± 1.60 × 109 L to 23.30 ± 1.61 × 109 L,
was observed in the control group (Figure 2C). On the
other hand neutrophils significantly decreased from a
baseline value of 78.20 ± 1.19 mm3 to 65.20 ± 3.48 mm3 in
the AKG treated group (p <0.001), meaning that patients
have no more infections and have re-established their
physiologic state. However a significant increase from a
baseline value of 71.45 ± 1.64 mm3 to 77.15 ± 1.11 mm3
was observed in the control group (p <0.05) (Figure 2B).sentation of the improvement in leukocytes in the AKG treated group
und remodeling; B. Schematic representation of the decrease of
nd a re-established physiologic state; C. Schematic representation of
esentations of the improvement in IgG, IgM and IgA respectively in
pecific antibody response and a definite reaction against sorting
of CRP in the AKG treated group meaning a slight antiinflammtory
n the AKG treated group *p < 0.05, ***p < 0.001.
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6.03 ± 0.41 mg/dl to 4.31 ± 0.38 mg/dl in the group receiv-
ing AKG (p <0.05), thus evidencing a slight antiinflamm-
tory effect of the product (Figure 2G). ESR decreased
from a baseline value of 27.18 ± 0.61 mm/hr to 26.60 ± 0.8
mm/hr in the group receiving AKG (Figure 2H).
The onset of complications such as broncopneumonia,
pleuritis, thromboembolism and wound disruption was re-
duced in the AKG treated group and the compliance to
the natural treatment was excellent without any adverse
effect; moreover WBC count restoration and IgG increase
might at least partially explain some sort of protection
against infectious agents and wound repair adverse events.
In the control group, along with previously cited com-
plications we also observed fever episodes almost due to
local and systemic low level of both non specific and
specific defence of these very old patients.
Very old aged surgical patients are quite fragile and re-
quire great care in order to avoid both localized or sys-
temic infections. Based on the folk medicine experience,
we tried the administration of AKG in the perioperative
phase in order to evaluate if its well reknown immuno-
modulating activity, even in the extreme life decade, might
be useful to prevent either local or systemic surgical com-
plications. Our patients reacted positively to AKG adminis-
tration and the compliance of the molecule was very high
with no drop out due to the optimal tolerance and safety.
Notwithstanding this small cohort of aged patients,
the concordant hemato-immunological effects of AKG
administration reduced both the number and the sever-
ity of complications in the treated patients and was
shown to be helpful for a quick and easy recovery.
Conclusions
In conclusion we suggest the opportunity to introduce this
nutraceutical product for an effective modulation of leu-
kocytes and soluble immune reactivity according with the
shark liver oil consumption trend in the northern Europe
countries folk medicine. The shark liver oil, accordingly
with the folk medicine tradition, administered in dosages
of 500 mg twice a day to very old people before surgical
treatment induced a significant increase of WBC, lympho-
cytes, IgM and IgA in the postoperative period. The com-
pound had not any kind of intolerance or side effects, and
the treated patients had a plain uneventful outcome not-
withstanding the fragile condition due to the extreme life
decade. For this reason it might be advisable a wider study
on a substantially bigger patients cohort focused on the
complication rate prevention or control.
Methods
Forty patients (mean age ± SEM, 97.20 ± 0.86 years; 57.5%
males, 42.5% females) were admitted to surgical outpatient
office for a preliminary evaluation of intervention feasibility.They were affected by the following surgical diseases:
umbilical hernia (2 cases), inguinal hernia (6 cases), lower
leg varyces (4 cases), laparoscopic cholecystectomy (8
cases), breast cancer (2 cases), hydrocele (4 cases), phymo-
sis (2 cases), skin cancer (2 spinocellular cancer, 2 basocel-
lular cancer and 2 melanomas), laparocele (4 cases), giant
lipoma (2 cases). Patients were equally distributed, in
terms of affecting disease, in two groups, control (12 males
and 8 females) and AKG (11 males and 9 females).
They were matched as case control along their recruit-
ment period which lasted from January 2011 up to
October 2013.
The preliminary selection of the patients to be treated
was related to the finding of a low total WBC count, shift
of the formula to neutrophilia (above 75% neutrophils)
and serum immunoglobulin level. In order to prevent
post op infection on a standardized basis we used ceftri-
axone 1 gr pre op followed by the same dosage daily i. m.
for the following 4 days. Antiinflammatory drugs were
ruled out from the schedule and for the pain control we
used only tramadol 100 mg 2-3 times a day and Phentanil
(Durogesic 25, 50, 100 mg tailored on pain intensity), in
order to avoid individual variations in biochemical pa-
rameters due to interfering molecules.
The investigated parameters, before and after 2 weeks
of surgical intervention, were inflammation indexes (re-
active C protein or CRP, erythrocyte sedimentation rate
or ESR), total leucocyte number and formula and serum
immunoglobulins (IgA and IgM).
The AKG (Lysi Italy, Manzano (UD), Italy; 500 mg of
pure alkylglycerols per capsule) administration (500 mg
twice a day) started at the first surgical admission visit
and prolonged along 4 weeks, with temporary with-
drawal from the morning of operation to the second
post op days.
This study was performed in accordance with the Dec-
laration of Helsinki and it was approved by the Institu-
tional Review Board at the Poliambulatorio del Secondo
Parere (Modena, Italy) were the study was performed.
Statistical analysis
Data were analyzed using GraphPad Prism 6 software
(GraphPad Software, Inc., La Jolla, CA, USA). All data
are presented as the means ± standard error of the mean
and were first checked for normality using the D’Agos-
tino-Pearson normality test. A paired Student’s t-test was
used to compare changes in values after 2 weeks treat-
ment versus baseline. Difference in values between the
two groups was analyzed using a two-way analysis of
variance (ANOVA) followed by Sidak’s multiple compari-
sons test.
Abbreviations
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